Actively Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Led by AstraZeneca · Updated on 2026-03-19
454
Participants Needed
95
Research Sites
264 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
D
Daiichi Sankyo
Collaborating Sponsor
AI-Summary
What this Trial Is About
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
CONDITIONS
Official Title
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, aged 18 years or older
- Diagnosed with advanced or metastatic malignancy
- Eastern Cooperative Oncology Group performance status of 0 or 1 with no decline in last 2 weeks
- Ability to provide a tumor tissue sample for analysis
- At least one measurable lesion (except for certain prostate cancer participants with non-measurable bone disease)
- Adequate bone marrow and organ function
- Expected to live at least 12 weeks
- Use of contraception consistent with local regulations during the study
- Women of childbearing potential must have a negative pregnancy test at screening
- Female participants must be postmenopausal for at least 1 year, surgically sterile, or using highly effective birth control
- Female participants must not donate or retrieve eggs during the study
- Male participants planning sexual activity with women of childbearing potential must be surgically sterile, abstain, or use highly effective contraception
- Male participants must not freeze or donate sperm during the study
- Able to provide informed consent
- Signed consent for optional genetic research prior to sample collection
You will not qualify if you...
- Any disease or condition that would make participation unsafe or interfere with study compliance
- History of another primary cancer except certain skin cancers or cured solid tumors
- Ongoing side effects from previous cancer treatments, excluding hair loss
- Irreversible toxicities unlikely to worsen with study treatment
- Untreated spinal cord compression or brain metastases
- Leptomeningeal carcinomatosis
- Significant corneal disease
- Active hepatitis or uncontrolled hepatitis B or C infection
- Uncontrolled infections requiring intravenous treatment
- Uncontrolled HIV infection
- Active tuberculosis infection
- Mean resting corrected QTcF above 470 ms or history of problematic QT prolongation
- Uncontrolled or significant heart disease
- History of non-infectious interstitial lung disease or pneumonitis requiring steroids
- Severe lung function impairment
- Recent use of chloroquine/hydroxychloroquine without washout
- Receipt of live vaccines within 30 days before study treatment
- Recent anticancer treatments without adequate washout or concurrent anticancer therapy
- Recent palliative radiotherapy to large bone marrow areas or limited field within 2 weeks
- Recent major surgery or trauma within 3 weeks or planned major surgery during study
- Prior treatment with TROP2-targeting therapies or deruxtecan-containing antibody drug conjugates
- Use of herbal or natural cancer treatments that could interfere with study drugs
- Previous participation in this study
- Participation in another clinical study with treatment or device within 4 weeks prior to study treatment
- Severe allergies to Dato-DXd or its components
- Involvement in study planning or conduct
- Unlikely to comply with study requirements
- Pregnancy, breastfeeding, or planning pregnancy during study
- Female participants must avoid breastfeeding from enrollment through at least 7 months after last dose of Dato-DXd
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 95 locations
1
Research Site
Los Angeles, California, United States, 90095
Actively Recruiting
2
Research Site
San Diego, California, United States, 92103
Withdrawn
3
Research Site
Santa Rosa, California, United States, 95403
Actively Recruiting
4
Research Site
Muncie, Indiana, United States, 47303
Withdrawn
5
Research Site
Kansas City, Kansas, United States, 66160
Withdrawn
6
Research Site
Boston, Massachusetts, United States, 02114
Withdrawn
7
Research Site
Boston, Massachusetts, United States, 02215
Completed
8
Research Site
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
9
Research Site
East Brunswick, New Jersey, United States, 08816
Actively Recruiting
10
Research Site
Albuquerque, New Mexico, United States, 87109
Actively Recruiting
11
Research Site
Commack, New York, United States, 11725
Actively Recruiting
12
Research Site
Cincinnati, Ohio, United States, 45219
Actively Recruiting
13
Research Site
Columbus, Ohio, United States, 43219
Actively Recruiting
14
Research Site
Portland, Oregon, United States, 97239
Withdrawn
15
Research Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
16
Research Site
Nashville, Tennessee, United States, 37232
Withdrawn
17
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
18
Research Site
Madison, Wisconsin, United States, 53792
Actively Recruiting
19
Research Site
Toronto, Ontario, Canada, M4N 3M5
Withdrawn
20
Research Site
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
21
Research Site
Montreal, Quebec, Canada, H2X 0A9
Withdrawn
22
Research Site
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
23
Research Site
Québec, Quebec, Canada, G1J 1Z4
Actively Recruiting
24
Research Site
Changsha, China, 410013
Withdrawn
25
Research Site
Chongqing, China, 400030
Withdrawn
26
Research Site
Guangzhou, China, 510060
Actively Recruiting
27
Research Site
Guangzhou, China, 510120
Withdrawn
28
Research Site
Hangzhou, China, 310020
Actively Recruiting
29
Research Site
Hefei, China, 230001
Withdrawn
30
Research Site
Shanghai, China, 200032
Actively Recruiting
31
Research Site
Shanghai, China, 200032
Not Yet Recruiting
32
Research Site
Shenyang, China, 110016
Withdrawn
33
Research Site
Wuhan, China, 430030
Withdrawn
34
Research Site
Wuhan, China, 430079
Withdrawn
35
Research Site
Xi'an, China, 710000
Withdrawn
36
Research Site
Zhengzhou, China, 450052
Actively Recruiting
37
Research Site
Bordeaux, France, 33076
Actively Recruiting
38
Research Site
Lyon, France, 69373
Actively Recruiting
39
Research Site
Marseille, France, 13273
Withdrawn
40
Research Site
Suresnes, France, 92150
Actively Recruiting
41
Research Site
Berlin, Germany, 10117
Withdrawn
42
Research Site
Essen, Germany, 45136
Withdrawn
43
Research Site
Hanover, Germany, 30625
Withdrawn
44
Research Site
München, Germany, 81377
Withdrawn
45
Research Site
Regensburg, Germany, 93053
Withdrawn
46
Research Site
Florence, Italy, 50139
Withdrawn
47
Research Site
Genova, Italy, 16132
Withdrawn
48
Research Site
Milan, Italy, 20132
Actively Recruiting
49
Research Site
Milan, Italy, 20141
Withdrawn
50
Research Site
Milan, Italy, 20162
Actively Recruiting
51
Research Site
Naples, Italy, 80131
Actively Recruiting
52
Research Site
Rome, Italy, 00168
Withdrawn
53
Research Site
Chūōku, Japan, 104-0045
Actively Recruiting
54
Research Site
Kashiwa, Japan, 277-8577
Actively Recruiting
55
Research Site
Kōtoku, Japan, 135-8550
Actively Recruiting
56
Research Site
Nagoya, Japan, 464-8681
Actively Recruiting
57
Research Site
Shinagawa-ku, Japan, 142-8666
Actively Recruiting
58
Research Site
Suita-shi, Japan, 565-0871
Actively Recruiting
59
Research Site
Gliwice, Poland, 44-102
Actively Recruiting
60
Research Site
Krakow, Poland, 31-501
Actively Recruiting
61
Research Site
Lodz, Poland, 92-213
Withdrawn
62
Research Site
Poznan, Poland, 61-866
Withdrawn
63
Research Site
Warsaw, Poland, 02-781
Actively Recruiting
64
Research Site
Seoul, South Korea, 03722
Actively Recruiting
65
Research Site
Seoul, South Korea, 05505
Actively Recruiting
66
Research Site
Seoul, South Korea, 06351
Actively Recruiting
67
Research Site
Seoul, South Korea, 110-744
Actively Recruiting
68
Research Site
Barcelona, Spain, 8035
Actively Recruiting
69
Research Site
Córdoba, Spain, 14004
Terminated
70
Research Site
Madrid, Spain, 28046
Actively Recruiting
71
Research Site
Málaga, Spain, 29010
Actively Recruiting
72
Research Site
Pamplona, Spain, 31008
Actively Recruiting
73
Research Site
Seville, Spain, 41013
Actively Recruiting
74
Research Site
Basel, Switzerland, 4031
Withdrawn
75
Research Site
Bellinzona, Switzerland, 6500
Withdrawn
76
Research Site
Sankt Gallen, Switzerland, 9007
Withdrawn
77
Research Site
Liou Ying Township, Taiwan, 736
Actively Recruiting
78
Research Site
Taipei, Taiwan, 100
Actively Recruiting
79
Research Site
Taipei, Taiwan, 11259
Actively Recruiting
80
Research Site
Taipei, Taiwan, 112
Actively Recruiting
81
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
82
Research Site
Ankara, Turkey (Türkiye), 06620
Actively Recruiting
83
Research Site
Ankara, Turkey (Türkiye), 06800
Actively Recruiting
84
Research Site
Cordaleo, Turkey (Türkiye), 35575
Actively Recruiting
85
Research Site
Edirne, Turkey (Türkiye), 22030
Actively Recruiting
86
Research Site
Kadıkoy/Istanbul, Turkey (Türkiye), 34722
Actively Recruiting
87
Research Site
Konya, Turkey (Türkiye), 42080
Actively Recruiting
88
Research Site
Pamukkale, Turkey (Türkiye), 20070
Actively Recruiting
89
Research Site
Samsun, Turkey (Türkiye), 55139
Withdrawn
90
Research Site
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
91
Research Site
Dundee, United Kingdom, DD1 9SY
Actively Recruiting
92
Research Site
London, United Kingdom, EC1A 7BE
Actively Recruiting
93
Research Site
London, United Kingdom, NW1 2PG
Actively Recruiting
94
Research Site
London, United Kingdom, SE1 9RT
Actively Recruiting
95
Research Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
14
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here